Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLIA transfer

This article was originally published in The Gray Sheet

Executive Summary

FDA intends to provide guidance on how requests for categorizations under the Clinical Laboratory Improvement Amendments of 1988 will be "administratively processed," the agency says in an Aug. 23 letter to in vitro diagnostic makers. The guidance will be made available prior to Jan. 31, 2000, the time at which the agency will begin handling the categorization duties currently conducted by the Centers for Disease Control and Prevention (1"The Gray Sheet" April 19, p. 3). A website also will be created to assist manufacturers with the transfer, FDA says

You may also be interested in...



CLIA Complexity Categorization Transfer From CDC To FDA Under Way

FDA expects to assume all duties related to the categorization of in vitro diagnostics conducted under the Clinical Laboratory Improvement Amendments from the Centers for Disease Control and Prevention by Jan. 31, 2000.

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel